Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.
Ryan H MoyGustavo Dos Santos FernandesPhilip JonssonJoanne F ChouAzfar BasuniaGeoffrey Y KuSree B ChalasaniMichelle S BoyarZoe GoldbergAvni M DesaiAmelia GablerMichael F BergerLaura H TangJaclyn F HechtmanDavid P KelsenMark SchattnerDavid H IlsonDavid B SolitBarry S TaylorNikolaus SchultzMarinela CapanuYelena Y JanjigianPublished in: The oncologist (2019)
Prognosis for metastatic esophagogastric cancer remains poor despite modern systemic therapy regimens. This phase II trial indicates that the combination of regorafenib and FOLFOX is well tolerated but does not add to the efficacy of first-line chemotherapy in metastatic esophagogastric cancer. Notably, recently reported data suggest potential synergy between regorafenib and the PD-1 inhibitor nivolumab. As this study demonstrates that regorafenib plus FOLFOX is safe, and combined chemotherapy and immunotherapy show favorable toxicity profiles, future studies combining immunotherapy with regorafenib and chemotherapy may be feasible.